Related Experiment Video
Updated: May 23, 2026

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
Published on: October 27, 2014
Cardiovascular effects of treatment with taxanes
Stavros Peroukides1, Alexandros Alexopoulos, Haralabos Kalofonos
1Department of Medical Oncology, School of Medicine, University of Patras, Patras, Greece. panio@upatras.gr
Abstract:
Taxanes are cytotoxic drugs that stabilize cellular microtubules and are among the most active of the antineoplastic agents being widely used in the treatment of cancer patients. Furthermore, taxanes comprise a valuable tool in interventional cardiology. Following treatment with taxanes, in many patients, the risk of cardiovascular complications has recently been noted. This review examines the cardiac toxicity of treatment with taxanes and their use in cardiology and analyzes issues in clinical practice.
Insights
Taxanes, used in cancer treatment and cardiology, can cause cardiac complications. This review examines their cardiac toxicity and clinical implications.
Area of Science:
- Oncology
- Cardiology
- Pharmacology
Background:
- Taxanes are potent antineoplastic agents that stabilize microtubules.
- They are increasingly utilized in interventional cardiology procedures.
- Recent observations highlight a risk of cardiovascular complications following taxane treatment.
Purpose of the Study:
- To review the cardiac toxicity associated with taxane therapy.
- To analyze the role of taxanes in interventional cardiology.
- To discuss clinical practice issues related to taxane-induced cardiotoxicity.
Main Methods:
- Literature review of studies on taxane-related cardiovascular events.
- Analysis of clinical data regarding taxane use in oncology and cardiology.
- Examination of current clinical guidelines and practice.
Main Results:
- Taxanes can induce various cardiovascular complications.
- The benefits of taxanes in cardiology must be weighed against potential cardiac risks.
- Managing cardiotoxicity is crucial for patient outcomes.
Conclusions:
- Taxane therapy requires careful cardiac monitoring.
- Further research is needed to elucidate mechanisms and improve management strategies.
- Balancing oncologic/cardiac benefits with cardiotoxicity risks is essential in clinical practice.
Related Concept Videos
Drugs that Stabilize Microtubules
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Cardiovascular Drugs: Classification based on Therapeutic Indications
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

